Compare QNC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNC | OBIO |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.4M | 362.4M |
| IPO Year | 2026 | 2020 |
| Metric | QNC | OBIO |
|---|---|---|
| Price | $1.23 | $5.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.43 |
| AVG Volume (30 Days) | ★ 1.0M | 287.1K |
| Earning Date | 11-18-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | $5,145.73 | N/A |
| Revenue Next Year | $505.80 | $33.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $1.25 | $3.34 |
| 52 Week High | $3.79 | $6.50 |
| Indicator | QNC | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.45 | 41.96 |
| Support Level | N/A | $3.67 |
| Resistance Level | $2.15 | $5.78 |
| Average True Range (ATR) | 0.13 | 0.34 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 2.38 | 1.70 |
Quantum eMotion Corp is a technology development company focused on developing and commercializing intellectual property in quantum-based cryptographic and cybersecurity solutions. The company delivers quantum-based security solutions in software and hardware that embed true quantum randomness at the chip level. Its software offerings include Sentry-Q for securing data across networks and applications; eFlux-Q, a cloud-based entropy distribution system for cryptographic systems and key generation; eCrypto-Q, a developer toolkit combining electron-based QRNG and post-quantum cryptography; and eHot-Q, a quantum-safe hot wallet SDK for digital asset protection. Its hardware solution includes eCore-Q, an electron-based QRNG providing high-speed entropy for cryptographic, AI, and IoT systems.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.